Ugur Sahin
September 10, 2019 06:29 AM EDTUpdated 10:42 AM
Financing

Fresh off the heels of mega fi­nanc­ing round, Ger­many's BioN­Tech makes $100M US IPO play

Natalie Grover

Reporter

Two months af­ter one of the largest sin­gle pri­vate fund­ing rounds for a biotech com­pa­ny in Eu­ro­pean his­to­ry, Ger­man can­cer drug de­vel­op­er BioN­Tech is gun­ning for a $100 mil­lion US IPO.

Hel­mut Jeg­gle
Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times